A Molecular Diagnostics Company

Making Early Cancer Detection the New Standard of Primary Care

Our Mission

For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.

Our Science

Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.


More accurate & reliable


More cost effective


fully scalable


significant societal impact

Our Social Impact

Latest News


ENMEDIA Explores Podcast Liquid Biopsy: What’s next?

June 30, 2023

Dr. Giulia Kennedy and Dr. Bernard Peperstraete talk with ENMEDIA about AcuamarkDx's solution to crack early cancer detection (long dash) a potential game changer for the liquid biopsy market.


Dr. Giulia Kennedy, AcuamarkDx, Board of Directors

AcuamarkDx Welcomes Giulia Kennedy, PhD, to the Board of Directors

May 03, 2023

Dr. Kennedy brings more than two decades of experience developing novel diagnostic technologies, most recently served as global chief scientific officer and chief medical officer at Veracyte, a global diagnostics company.


AcuamarkDx Secures $11.3 Million Series A Funding to Advance Innovative Assays for Improved, Cost-Effective Early-Cancer Detection

July 19, 2022

The round was led by Claudio Del Vecchio, former chairman, CEO, and owner of Brooks Brothers Group, Inc. and joined by Bruker Corporation.  

AcuamarkDx logo

Acuamark Diagnostics develops technology that allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before cancer becomes untreatable.

Contact Us